Human G1/S-specific cyclin-E1(CCNE1) ELISA kit

Instructions
Code CSB-EL004817HU
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name cyclin E1
Alternative Names CCNE ELISA Kit; Ccne1 ELISA Kit; CCNE1_HUMAN ELISA Kit; cyclin E variant ex5del ELISA Kit; cyclin E variant ex7del ELISA Kit; Cyclin E1 ELISA Kit; Cyclin Es ELISA Kit; Cyclin Et ELISA Kit; CyclinE ELISA Kit; G1/S specific cyclin E ELISA Kit; G1/S-specific cyclin-E1 ELISA Kit
Abbreviation CCNE1
Uniprot No. P24864
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates, cell lysates
Detection Range 25 pg/mL-1600 pg/mL
Sensitivity 6.25 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Cell Biology
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human CCNE1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)
1:1 Average % 100
Range % 95-104
1:2 Average % 95
Range % 90-100
1:4 Average % 91
Range % 86-95
1:8 Average % 84
Range % 80-88
Recovery
The recovery of human CCNE1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range
Serum (n=5) 93 89-97
EDTA plasma (n=4) 88 84-92
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/ml OD1 OD2 Average Corrected
1600 1.921 1.837 1.879 1.741
800 1.294 1.228 1.261 1.123
400 0.819 0.783 0.801 0.663
200 0.543 0.519 0.531 0.393
100 0.362 0.376 0.369 0.231
50 0.280 0.301 0.291 0.153
25 0.207 0.194 0.201 0.063
0 0.141 0.135 0.138  
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 5-7 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Background

Function
(From Uniprot)
Essential for the control of the cell cycle at the G1/S (start) transition.
Gene References into Functions
  1. miR-874 inhibits CCNE1 expression during growth factor deprivation and that miR-874 down-regulation in osteosarcomas leads to CCNE1 up-regulation and more aggressive growth phenotypes. PMID: 29109143
  2. Amplified/cyclin E1(hi) and non-amplified/cyclin E1(hi) tumors have different pathological and biological characteristics and clinical outcomes indicating that they are separate subsets of cyclin E1(hi) HGSOC. PMID: 30209015
  3. Breast cancer recurrence-free interval was significantly worse in patients with cyclin E (LMW-E)-positive tumors who received aromatase inhibitor (AI) neoadjuvant therapy, compared with those with LMW-E negative tumors. PMID: 28947566
  4. in a series of human biopsies, non-metastatic SCCs displayed a higher degree of chromosomal alterations and higher expression of the S phase regulator Cyclin E and the DNA damage signal gammaH2AX than the less aggressive, non-squamous, basal cell carcinomas. However, metastatic Squamous cell carcinoma lost the gammaH2AX signal and Cyclin E, or accumulated cytoplasmic Cyclin E. PMID: 28661481
  5. Cytoplasmic cyclin E identifies patients with the highest likelihood of recurrence consistently across different patient cohorts and subtypes. These patients may benefit from alternative therapies targeting the oncogenic isoforms of cyclin E. PMID: 27881578
  6. our results validate the assumption that CBX7 is a tumor suppressor of gliomas. Moreover, CBX7 is a potential and novel prognostic biomarker in glioma patients. We also clarified that CBX7 silences CCNE1 via the combination of CCNE1 promoter and the recruitment of HDAC2. PMID: 28460453
  7. Our findings suggest that gene copy-number gain and upregulation of CCNE1 occur in ovarian clear cell carcinoma and are associated with a worse clinical outcome, dictating the survival of early-stage patients. PMID: 27767100
  8. YAP/ TAZ pathways contribute to the proliferation/quiescence switch during colon cancer 5FU treatment according to the concerted regulation of Cyclin E1 and CREB PMID: 27527859
  9. Silencing of CDCA5 suppresses proliferation of gastric cancer cells by inducing G1-phase arrest via downregulating CCNE1. PMID: 29326043
  10. Analysis of genomic data from TCGA demonstrated coamplification of CCNE1 and AKT2 Overexpression of Cyclin E1 and AKT isoforms, in addition to mutant TP53, imparted malignant characteristics in untransformed fallopian tube secretory cells, the dominant site of origin of high-grade serous ovarian cancer PMID: 27663592
  11. Finding suggest that amplification of CCNE1 serves as one mechanism for the development of some serous tubal intraepithelial carcinomas. PMID: 27443516
  12. Prognostic gene sets based on the 13 genes were developed, and their prognostic values were verified in three independent patient cohorts (n=501). Among them, a signature of CCNE1 and its coexpressed genes was significantly associated with disease progression and validated in the independent cohorts. PMID: 28082741
  13. Cyclin E1 mRNA and protein expressions were suppressed. PMID: 26603262
  14. The opposing effects of ORC1 (represor) and CDC6 (gene activator) in controlling the level of Cyclin E ensures genome stability and a mechanism for linking directly DNA replication and cell division commitment. PMID: 27458800
  15. High cyclin E expression is associated with breast cancer. PMID: 28760857
  16. High CCNC1 expression is associated with inflammatory breast cancer. PMID: 28107181
  17. Inhibition of cell division cycle associated 2 (CDCA2) suppressed the proliferation of lung adenocarcinoma (LAC) cells via G1 phase arrest by downregulating cyclin E1(CCNE1), while overexpression of CDCA2 promoted LAC cells proliferation by upregulating CCNE1. PMID: 28423619
  18. a PI3K/PKCiota/cyclin E signaling pathway as a therapeutic target during ovarian tumorigenesis PMID: 26279297
  19. Amplification of 19q12 CCNE1/URI was found in 10.4% (28/270) and was significantly associated with type II endometrial cancer (EC) high grade, advanced FIGO stage, and aberrant tumor supressor p53 expression. PMID: 27582547
  20. Results show that cyclin E1 and CDK2 participate in STC1 promoting cell proliferation of prostate neoplasm cells. PMID: 28350121
  21. cyclin E is specifically dephosphorylated at S384 by the PP2A-B56 phosphatase, thereby uncoupling cyclin E degradation from cyclin E-CDK2 activity PMID: 28137908
  22. These results provide evidence that ARTD1 regulates cell cycle re-entry and G1/S progression via cyclin E expression and p27(Kip 1) stability independently of its enzymatic activity, uncovering a novel cell cycle regulatory mechanism. PMID: 27295004
  23. These results demonstrate a repressor role for NFAT1 in cell cycle progression and Cyclin E expression in B lymphocytes, and suggest a potential function for NFAT1 protein in B cell malignancies. PMID: 27399331
  24. High CCNE1 amplification and expression is associated with breast cancer. PMID: 26810187
  25. CCNE1/REL gene interaction might play pivotal roles in the occurrence and development of Postmenopausal Osteoporosis. PMID: 26676054
  26. These results indicate that miR-25 has anti-apoptosis roles in AGS cells, possibly via inhibiting FBXW7 and thus promoting oncogenes, such as CCNE1 and MYC. PMID: 27120728
  27. Cyclin E-driven OvCa cells appeared addicted to glucose metabolism via TCA. Combined CDKi with modalities targeting TCA, like SDHA inhibition showed promising effects for this genotype. Combined blockade of CDK and SDH, both genetically and pharmaceutically, showed synergy and resulted in inhibited proliferation, migration, invasion and migration in A2780 cells PMID: 26826064
  28. Over-expression of CCNE1 is associated with non-small cell lung cancer. PMID: 26771237
  29. High levels of cyclin E are a predicator of poor prognosis among patients with gastrointestinal cancer. [meta-analysis] PMID: 25627202
  30. The effects of CCNE1 knockdown were dependent on the CCNE1 expression status. PMID: 26647729
  31. Data show that melanoma antigen, family C, 2 protein (MAGE-C2) binds with RING-box protein 1 (Rbx1) and Cullin 1, and regulates cyclin E stability in melanoma cells. PMID: 26540345
  32. The findings suggest that the role of cyclin E and tumor specific low molecular weight isoforms as mediators of tumorigenesis is in part dependent on p53 context. PMID: 26625764
  33. Ad-cycE can target cyclin E overexpression in cancer cells and repress tumor growth in syngeneic mouse models. PMID: 26475304
  34. ovary tumors with elevated CCNE1 expression may be staged for Cdk2-targeted therapy PMID: 26204491
  35. our findings identify a novel mechanism of cyclin E-mediated Mcl-1 regulation in human cancer PMID: 26219338
  36. miR-15b might be involved in termination of osteoblastic cells proliferation by arresting them at G0/G1 phase through direct targeting cyclin E1. PMID: 26007664
  37. A significant correlation between cyclin E1 amplification and deletions at a number of the genomic loci in breast cancer. PMID: 25959964
  38. These results indicate cyclin E1 is downregulated by both miR-497 and miR-34a, which synergistically retard the growth of human lung cancer cells. PMID: 25909221
  39. MicroRNA-30c-2-3p negatively regulates NF-kappaB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer. PMID: 25732226
  40. Results show that miR-16 and HuR co-regulate the cyclin E1 mRNA without influencing each other's binding or expression. miR-16 regulation predominates, blocking upregulation of cyclin E1 by HuR. PMID: 25830480
  41. Expression of Notch1, -2, and -3, CDK2, and CCNE1 was significantly decreased by upregulation of ALDH1A1 in A549 cells, but increased by its interruption in A549s cells. PMID: 24671051
  42. Results show that CCNE1 and BRD4 on chromosome 19 were amplified/overexpressed in a substantial cases of epithelial ovarian cancer with no involvement of BRCA genes. PMID: 25892415
  43. This study indicates that CCNE1 rs1406 polymorphism may contribute to BC risk PMID: 25159285
  44. Suppression of NF90 caused a decrease in the half-life of cyclin E1 mRNA PMID: 25399696
  45. miR-144-5p functions as tumour suppressor in BC cells. CCNE1 and CCNE2 were directly regulated by miR-144-5p and might be good prognostic markers for survival of bladder cancer patients PMID: 26057453
  46. HOXA7 promotes cell proliferation, and these changes are mediated by cyclin E1/CDK2 PMID: 25501982
  47. Aurora-A/HURP relays cell transforming signal to NF-kappaB, and the HURP/NF-kappaB complex is engaged in the regulation of cyclin E1 expression. PMID: 25289861
  48. Contrary to previous literature, we found a correlation between cyclin E expression and prognosis. Further large-scale studies are required to confirm our findings. PMID: 26026100
  49. Global gene expression profiling identifies ALDH2, CCNE1 and SMAD3 as potential prognostic markers in upper tract urothelial carcinoma. PMID: 25408144
  50. The cell cycleassociated proteins cyclin E and p27kip1 may have contributed to this antitumor effect. PMID: 25310086

Show More

Hide All

Subcellular Location Nucleus
Protein Families Cyclin family, Cyclin E subfamily
Tissue Specificity Highly expressed in testis and placenta. Low levels in bronchial epithelial cells.
Database Links

HGNC: 1589

OMIM: 123837

KEGG: hsa:898

STRING: 9606.ENSP00000262643

UniGene: Hs.244723

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2021 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1